ארצות הברית - אנגלית - NLM (National Library of Medicine)

profounda, inc. - miltefosine (unii: 53ey29w7ec) (miltefosine - unii:53ey29w7ec) - miltefosine 50 mg - impavido (miltefosine) capsules are indicated in adults and pediatric patients 12 years of age and older weighing greater than or equal to 30 kg (66 lbs) for the treatment of: limitations of use: impavido is contraindicated in patients who are pregnant. based on animal data, miltefosine may cause fetal harm. [see boxed warning, warnings and precautions (5.1) and use in specific populations (8.1)]. impavido is contraindicated in patients who have sjögren-larsson-syndrome [see clinical pharmacology (12.3)] . impavido is contraindicated in patients who are hypersensitive to miltefosine or any impavido excipients. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to impavido during pregnancy. healthcare providers are encouraged to register patients by calling 1-866-588-5405. risk summary impavido is contraindicated during pregnancy. based on data from animal reproduction studies, impavido may cause embryo-fetal toxicity when administered to pre

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - paclitaxel, quantity: 30 mg - injection, concentrated - excipient ingredients: peg-35 castor oil; ethanol absolute - - primary treatment of ovarian cancer in combination with a platinum agent.. - treatment of metastatic carcinoma of the ovary after failure of standard therapy.. - treatment of metastatic carcinoma of the breast after failure of standard therapy.. - adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide.. - treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin?), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease.. - in combination with gemcitabine (gemzar?), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. . - for the treatment of non-small cell lung cancer (nsclc).

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - paclitaxel, quantity: 100 mg - injection, concentrated - excipient ingredients: ethanol absolute; peg-35 castor oil - - primary treatment of ovarian cancer in combination with a platinum agent.. - treatment of metastatic carcinoma of the ovary after failure of standard therapy.. - treatment of metastatic carcinoma of the breast after failure of standard therapy.. - adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide.. - treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin?), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease.. - in combination with gemcitabine (gemzar?), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. . - for the treatment of non-small cell lung cancer (nsclc).

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - paclitaxel, quantity: 300 mg - injection, concentrated - excipient ingredients: ethanol; citric acid; peg-35 castor oil - primary treatment of ovarian cancer in combination with a platinum agent. treatment of metastatic carcinoma of the ovary after failure of standard therapy. treatment of metastatic carcinoma of the breast after failure of standard therapy. adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease. in combination with gemcitabine (gemzar), the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment of non-small cell lung cancer (nsclc).

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - paclitaxel, quantity: 100.2 mg - injection, concentrated - excipient ingredients: ethanol; peg-35 castor oil; citric acid - primary treatment of ovarian cancer in combination with a platinum agent. treatment of metastatic carcinoma of the ovary after failure of standard therapy. treatment of metastatic carcinoma of the breast after failure of standard therapy. adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease. in combination with gemcitabine (gemzar), the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment of non-small cell lung cancer (nsclc).

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - paclitaxel, quantity: 30 mg - injection, concentrated - excipient ingredients: peg-35 castor oil; citric acid; ethanol - primary treatment of ovarian cancer in combination with a platinum agent. treatment of metastatic carcinoma of the ovary after failure of standard therapy. treatment of metastatic carcinoma of the breast after failure of standard therapy. adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease. in combination with gemcitabine (gemzar), the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment of non-small cell lung cancer (nsclc).

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - paclitaxel, quantity: 150 mg - injection, concentrated - excipient ingredients: ethanol; peg-35 castor oil; citric acid - primary treatment of ovarian cancer in combination with a platinum agent.. treatment of metastatic carcinoma of the ovary and of the breast after failure of standard therapy.. adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide.. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that overexpress her-2 and who have not received previous chemotherapy for their metatastic disease.. paclitaxin, in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or . metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.. treatment of non-small cell lung cancer (nsclc).

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - paclitaxel, quantity: 300 mg - injection, concentrated - excipient ingredients: ethanol; peg-35 castor oil; citric acid - primary treatment of ovarian cancer in combination with a platinum agent.. treatment of metastatic carcinoma of the ovary and of the breast after failure of standard therapy.. adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide.. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that overexpress her-2 and who have not received previous chemotherapy for their metatastic disease.. paclitaxin, in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or . metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.. treatment of non-small cell lung cancer (nsclc).

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - paclitaxel, quantity: 30 mg - injection, concentrated - excipient ingredients: ethanol; peg-35 castor oil; citric acid - primary treatment of ovarian cancer in combination with a platinum agent.. treatment of metastatic carcinoma of the ovary and of the breast after failure of standard therapy.. adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide.. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that overexpress her-2 and who have not received previous chemotherapy for their metatastic disease.. paclitaxin, in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or . metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.. treatment of non-small cell lung cancer (nsclc).

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - paclitaxel, quantity: 100 mg - injection, concentrated - excipient ingredients: peg-35 castor oil; ethanol; citric acid - primary treatment of ovarian cancer in combination with a platinum agent.. treatment of metastatic carcinoma of the ovary and of the breast after failure of standard therapy.. adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide.. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that overexpress her-2 and who have not received previous chemotherapy for their metatastic disease.. paclitaxin, in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or . metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.. treatment of non-small cell lung cancer (nsclc).